$LPTX News
Last published 12mo ago
- 12mo agoLPTXCypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial ResultsPR NewswireCypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients with...
- 12mo agoLPTXCYPHLeap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury StrategyPR NewswireLeap Therapeutics, Inc. (Nasdaq: LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury ...
- 1y agoLPTXLeap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025PR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final ...
- 1y agoLPTXLeap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyPR NewswireLeap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has ...
- 1y agoGTBPLPTXIOBTCELC+1Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 BillionPR NewswireUSA News Group News Commentary – Major pharmaceutical companies are unveiling breakthrough cancer data at the European Society for Medical Oncology...
- 1y agoLPTXLeap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyPR NewswireLeap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 ...
- 1y agoLPTXLeap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025PR NewswireLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it...
- 1y agoLPTXLeap Therapeutics Reports Second Quarter 2025 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 1y agoLPTXLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 1y agoLPTXLeap Therapeutics Reports First Quarter 2025 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 1y agoGMDALPTXPPBTWSTPurple Biotech Appoints Shai Lankry as Chief Financial OfficerGlobeNewswireU.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a
- 1y agoLPTXLeap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it...
- 1y agoLPTXLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerPR NewswireLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it...
- 1y agoLPTXLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 1y agoLPTXLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented...
- 1y agoLPTXLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...
- 1y agoLPTXLeap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferencePR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 1y agoLPTXLeap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferencePR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 1y agoLPTXLeap Therapeutics Reports Third Quarter 2024 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 2y agoLPTXLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsPR NewswireLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...
- 2y agoLPTXLeap Therapeutics Reports Second Quarter 2024 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 2y agoLPTXLeap Therapeutics Reports First Quarter 2024 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 2y agoLPTXLeap Therapeutics Announces $40 Million Private PlacementPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it...
- 2y agoLPTXLeap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 2y agoLPTXLeap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new...
- 2y agoLPTXLeap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferencePR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 2y agoLPTXLeap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 2y agoLPTXLeap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 2y agoLPTXLeap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferencePR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...
- 2y agoLPTXLeap Therapeutics Reports Third Quarter 2023 Financial ResultsPR NewswireLeap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
- 3y agoACHLADVMAVIRBOLT+610 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical
- 3y agoLPTXLeap Therapeutics to Participate at Upcoming Investor ConferencesPR NewswireCAMBRIDGE, Mass., Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi,
- 3y agoLPTXLeap Therapeutics Reports Second Quarter 2023 Financial ResultsPR NewswireCAMBRIDGE, Mass., Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second
- 3y agoLPTXLeap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsPR NewswireCAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early
- 3y agoLPTXLeap Therapeutics Announces Reverse Stock SplitPR NewswireCAMBRIDGE, Mass., June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a
- 3y agoLPTXLeap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingPR Newswire19.5 months median OS in the overall first-line patient population, exceeding current benchmarksLong-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population,
- 3y agoLPTXLeap Therapeutics Reports First Quarter 2023 Financial ResultsPR NewswireCAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for first
- 3y agoLPTXLeap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingPR NewswireCAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be
- 3y agoLPTXLeap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsPR NewswireCAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been
- 3y agoLPTXLeap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsPR NewswireCAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the
- 3y agoLPTXLeap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01PR NewswireDisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass., March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company
- 3y agoALBOALRCEMILPTXMoore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoALRATCXCEMILPTXMoore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law FirmPR NewswireNEW YORK, Feb. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoLPTXLeap Therapeutics Acquires Flame BiosciencesPR NewswireAdds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding
- 3y agoLPTXLeap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology ConferencePR NewswireCAMBRIDGE, Mass., Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi,
- 3y agoLPTXLeap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare ConferencePR NewswireCAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi,
- 3y agoLPTXLeap Therapeutics Reports Third Quarter 2022 Financial ResultsPR NewswireCAMBRIDGE, Mass., Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the
- 4y agoLPTXLeap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual MeetingPR Newswire55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass.,
- 4y agoLPTXLeap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsPR NewswireCAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has
- 4y agoLPTXLeap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction CancerPR NewswireCAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has